# Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis

> **NCT02921971** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 97 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** SAR156597
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02921971
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-21
- **Primary completion:** 2019-01-14
- **Final completion:** 2019-04-01
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921971, "Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02921971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*